Noroclav vet.

1 x 10 stk

Tablett

Innholdstoffer

Amoxicillin (Amoxicillin-trihydrat) : 200 mg

Klavulansyre (Kaliumklavulanat) : 50 mg

ATC-kode

QJ01CR02 amoksicillin og beta-laktamasehemmer

QJ01CR Komb. av penicilliner, inkludert beta-laktamasehemmere

QJ01C Beta-laktam antibakterielle midler, penicilliner

QJ01 Antibakterielle midler til systemisk bruk

QJ Antiinfektiva til systemisk bruk

Dyrearter

Dogs.

Indikasjoner

For the treatment of the following infections caused by βlactamase producing strains of bacteria sensitive to amoxicillin in combination with clavulanic acid:

• Skin infections (including superficial and deep pyodermas) caused by susceptible Staphylococci.

• Urinary tract infection caused by susceptible Staphylococci or Escherichia coli.

• Respiratory infections caused by susceptible Staphylococci.

• Enteritis caused by susceptible Escherichia coli.

It is recommended to carry out suitable tests for sensitivity testing when initiating the treatment. The treatment should only proceed if sensitivity is proven to the combination.

Dosering og tilførselvei

Oral use. The dosage is 12.5 mg combined actives/kg bodyweight twice daily. The tablets may be crushed and added to a little food.

The following table is intended as a guide to dispensing the product at the standard dose rate of 12.5 mg of combined actives/kg twice daily.

Bodyweight (kg)	Number of tablets twice daily
19-20	1
21-30	1.5
31-40	2
41-50	2.5
More than 50	3

Duration of therapy:

Routine cases involving all indications: The majority of cases respond to between 5 and 7 days therapy.

Chronic or refractory cases: In these cases where there is considerable tissue damage, a longer course of therapy may be required in that it allows sufficient time for damaged tissue to repair.

Bivirkninger

Dogs:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Gastrointestinal disorders (Diarrhoea, Vomiting)

Allergic reactions (e.g. skin reaction, anaphylaxis) ¹

Hypersensitivity reaction²

¹ In these cases, treatment should be withdrawn.

² Unrelated to dose

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorization holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.